Method for T Lymphocyte Immunosupression

Tech ID: 96-04

Researchers from National Jewish Health have developed and tested a novel method for T lymphocyte immunosuppression. The technology is based on conjugating a CD4 or CD2 molecule with an antibody specific for a cell surface marker. Therefore this technology inhibits CD4+ or CD4+ together with CD8+ T cells, respectively, immune stimulatory cells, without affecting other immune functions.

Potential Applications

  • Graft rejection
  • Autoimmune diseases

Advantages of Invention
Only lymphocytes that are specific for antigens found on the grafted cells are target, eliminating any broad immunosuppression currently obtained with traditional treatments.

State of Development
Technology has been demonstrated in vitro to inhibit CD4+ T cells by conjugating engineered antibody that express CD4 or CD2 molecules onto immune stimulatory cells.

Further R&D Required
Demonstrating the efficacy of the technology in vivo.

US patents # 6,060,054 and 6,264,950


Uwe Staerz, MD, PhD

Licensing Status
This technology is available for licensing


For Further Information, Contact:
Emmanuel Hilaire, PhD
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352

Bookmark and Share

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.